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Abstract
Background: Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and
excessive utilization of outpatient services and long-term care. This analysis examined health care resource
utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting
therapy (RLAT).
Methods: Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month
observational study designed to examine real-world treatment outcomes by prospectively following patients with
schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the
previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The
health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason,
psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess
pre-event and postevent rates per person-year (PY).
Results: The primary medical resource utilization analysis included 435 patients who had a baseline visit, ≥1
postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits
per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29
hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a
difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related
hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits
were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased
significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001).
Conclusion: The results suggest that treatment with RLAT may result in decreased hospitalizations for patients
with schizophrenia.
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Schizophrenia is a chronic mental health disorder asso-
ciated with increased hospital admissions and excess uti-
lization of outpatient services and long-term care [1]. In
2002, direct and indirect costs attributed to schizophre-
nia in the United States were $63 billion [1]. Although
the lifetime prevalence of schizophrenia is approximately
1.5%, the cost of treatment accounts for nearly 2.5% of
total health care expenditures in the United States [2].
Therapeutic intervention for schizophrenia includes use
of antipsychotic medications in the acute phase of the
disease, followed by long-term maintenance therapy.
Many patients respond to initial treatment of first-epi-
sode schizophrenia but then experience a relapse,
defined as rehospitalization, symptom re-emergence, or
both. Relapse has been strongly associated with partial
adherence or nonadherence to treatment [3]. Poor
adherence to antipsychotic medications has also been
associated with rehospitalization and higher hospitaliza-
tion costs [4]. Therefore, to reduce health care costs
incurred by patients with schizophrenia, adherence to
therapeutic regimens should be improved. Treatments
that reduce health care resource utilization in patients
with schizophrenia have the potential to reduce overall
health care costs substantially [4]. Such treatments may
also reduce societal or indirect costs by reducing the
care time required by caregivers and by providing
patients opportunities to return to employment.
Risperidone long-acting therapy (RLAT), a second-
generation injectable atypical antipsychotic approved for
the treatment of schizophrenia, has been found to
improve clinical symptoms and decrease relapse rates
[5-9]. The injectable formulation of RLAT may facilitate
improved treatment adherence, which can lead to
improved patient outcomes and lower utilization of
health care services. As conventional long-acting inject-
able antipsychotics have been found to decrease the
one-year risk of hospitalization (21% to 36%) [10,11],
previous studies suggest that RLAT may result in
decreased hospitalization. In a 12-month study [7], 18%
of patients were rehospitalized during the trial, while in
another study, where 106 patients served as their own
controls, hospitalization decreased to 42% (p < .001)
after RLAT initiation compared with before initiation
(75%) [12].
The Schizophrenia Outcomes Utilization Relapse and
Clinical Evaluation (SOURCE) was an observational
study designed to examine real-world treatment out-
comes by prospectively following patients with schizo-
phrenia initiated on RLAT. The health care resource
utilization outcomes measures (per person-year [PY])
observed in this study were hospitalizations for any rea-
son (defined as all-cause hospitalizations), psychiatric-
related hospitalizations, and emergency room (ER) visits.
The follow-up period for the SOURCE study was up to
24 months, in order to investigate clinical outcomes
related to maintenance treatment with antipsychotic
medications in patients with schizophrenia.
Methods
Study Design
The SOURCE project was a 24-month, multicenter, pro-
spective, longitudinal, observational study conducted
from September 2004 to January 2006 at 67 community
mental health centers and Veterans Administration hos-
pitals in the United States. The study protocol and sub-
ject informed consent form were reviewed and approved
by an institutional review board. Patients eligible for
enrollment were aged 18 years or older, were appropri-
ate for initiation of RLAT, had a physician-based diag-
nosis of schizophrenia according to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), and had signed the informed consent form.
Patients who were at imminent risk of injuring them-
selves or others or of causing significant damage to
property, who were hypersensitive to RLAT or any of its
components, or who had been treated with investiga-
tional agents within the previous 30 days were not eligi-
ble for enrollment.
The recommended initial RLAT dosage is 25 mg every
2 weeks by deep intramuscular gluteal injection. Patients
not responding to 25 mg may benefit from a higher
dose of 37.5 mg or 50 mg [13]. Patients were defined as
having received RLAT if they had >1 record for RLAT
in the injection log within 28 days before each study
visit. This study had a naturalistic design: after enroll-
ment, specific treatments or medical interventions were
not mandated, so treatments for schizophrenia could
have been stopped, started, or changed throughout the
study, as deemed appropriate by the treating physician.
Study site monitoring was not conducted. The safety
and efficacy data from this study population has been
described [14].
At the baseline visit, dates of prior hospitalizations
and ER visits were obtained for the previous 12 months.
At each 3-month visit, subsequent hospitalizations and
ER visits since last study visit were obtained, if available,
through patient or clinician reports. Hospitalizations
were categorized as psychiatric-related (nonsocial rea-
son) or “other"; ER visits were categorized as psychia-
tric-related or “other medical problem.” Hospitalization
for any reason (all-cause hospitalizations) were also
determined and categorized as due to psychotic disease,
social reasons, or “other.” Dates of psychiatric events,
defined as deliberate self-injury, clinically significant sui-
cidal or homicidal ideation, or violent behavior resulting
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erty damage, were also collected every 3 months.
Statistical Methods
Each patient served as his or her own control. Patients
were included in the analysis if they had a baseline visit,
>1 postbaseline visit, and valid hospitalization dates.
Because this was an analysis of a closed registry, no
sample size calculation was performed for this analysis.
All eligible patients were used in the analysis. The num-
bers of outcomes per PY prior to baseline (visit 1) and
during all available postbaseline visits were calculated.
When comparing resource utilization between the 12-
month period before study entry (preperiod) and the
postbaseline period, it was necessary to account for dif-
ferent lengths of follow-up times among patients. The
incidence densities for hospitalization and ER visit were
calculated. Incidence density was defined as the total
number of events for the study population divided by
the total length of time the population was at risk for
these events in follow-up years. The bootstrap resam-
pling method was used to calculate confidence intervals
(CIs), and p-values were used to examine the difference
between the prebaseline and postbaseline periods for
hospitalization and ER visits.
A subgroup analysis was performed on patients with
>2 RLAT injections who had valid dates in the prebase-
line period. The percentage of patients with >1 hospita-
lization was evaluated for the prebaseline and
postbaseline periods. Percentages were tested with a
McNemar test.
Categorical measures were summarized using frequen-
cies and percentages. Continuous measures were sum-
marized using mean, standard deviation (SD), minimum,
maximum, and median. SAS software (Version 9.1, SAS
Institute Inc., Cary, NC, USA) was used for all analyses.
All tests were two-tailed and conducted at the 5% signif-
icance level.
Results
Demographic Characteristics
A total of 532 patients were enrolled in the study at 66
study sites. Approximately 18% of patients did not
return for the 3-month visit, and 13% did not return for
the 6-month visit. At the 24-month visit, 210 (39.5%)
patients remained in the study. A total of 435 patients
who had a baseline visit, >1 postbaseline visit, and valid
hospitalization dates were studied for the primary medi-
cal resource utilization analysis.
As shown in Table 1, the mean (SD) age of the study
population (n = 435) was 41.9 (12.6) years, and 66.7% of
the patients were male. The mean (SD) duration of ill-
ness was 17.6 (12.1) years. Twenty-two patients (5.1%)
experienced an inpatient hospitalization at baseline. In
this sample, 321 patients (73.8%) were initiated on the
25-mg dose of RLAT, 62 (14.3%) on the 37.5-mg dose,
and 51 (11.5%) on the 50-mg dose (one patient had
missing data). Additionally, in 38.9% of patients the
investigator reported that they received other antipsy-
chotics in addition to RLAT during the study. Of the
patients in this sample, 419 (96.3%) had evidence of
RLAT use at visit 1; of the 210 patients who attended
visit 9, 160 (76.3%) had evidence that they were receiv-
ing RLAT.
For the subgroup analysis of the 343 patients who had
received >2 RLAT injections and had a fixed observation
period of 12 months, the mean (SD) age of the study
population was 42.1 (12.8) years, and 66.5% of the
patients were male. The mean (SD) duration of illness
was 24.0 (8.6) years.
Resource Utilization
The number of hospitalizations (all-cause and psychia-
tric-related) and ER visits per PY declined significantly
(p < .0001) after initiation with RLAT. A 41% decrease
(difference of -0.29 hospitalizations per PY [95% CI:
- 0 . 3 9t o- 0 . 1 8 ]f r o mb a s e l i n e )i na l l - c a u s eh o s p i t a l i z a -
tions a 56% decrease (a difference of -0.35 hospitaliza-
tions per PY [95% CI: -0.44 to -0.26] from baseline) in
psychiatric-related hospitalizations, and a 40% decrease
(-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10]
from baseline) in ER visits were also observed after
RLAT was initiated (Figure 1). Of those 343 patients
who had received >2 RLAT injections and who had a
fixed observation period of 12 months, the percentage
of patients with >1 psychiatric-related hospitalization
declined from 34.7% in the pre-RLAT period to 20.7%
in the post-RLAT period (p < .0001; McNemar test; Fig-
ure 2).
Discussion
Hospitalization is the major cost driver in the treatment
of schizophrenia; 79% of the direct costs of schizophre-
n i aa r ed u et oh o s p i t a l i z a t i on or other residential care
Table 1 Demographic and patient characteristics
N = 435
Age, y, mean (SD) 41.9 (12.6)
a
Gender, male, % 66.7
Years since diagnosis, mean (SD) 17.6 (12.1)
b
Hospitalized in prior year, % 39.3
Inpatient hospitalization at baseline, n (%) 22 (5.1%)
CGI-S score, mean (SD) 3.9 (1.2)
GAF score, mean (SD) 53.1 (13.7)
c
CGI-S, Clinical Global Impression-Severity; GAF, Global Assessment
Functioning; SD, standard deviation.
an = 433;
bn = 427;
cn = 434.
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collected efficacy, resource utilization, and safety data of
United States patients with schizophrenia for 24 months,
demonstrated that the initiation of RLAT significantly
reduced the number of hospitalizations for any reason
and ER visits and decreased the percentage of psychia-
tric-related hospitalization by 14%. These results are in
agreement with those of previous studies, which have
shown that RLAT reduces hospitalization, ER visits,
resource utilization, and inpatient bed days.
In the electronic Schizophrenia Treatment Adherence
Registry (eSTAR) study for Spain [15], a higher percen-
tage of patients (89.1% versus 67%) did not require
hospitalization at 12 months after switching to RLAT,
compared retrospectively with the patients in same per-
iod receiving the previous antipsychotic treatment. Simi-
lar results were observed at 24 months (85.2% versus
60%) [15]. In a retrospective study conducted in the
United Kingdom, data on the number of hospitalizations
and inpatient bed days were collected from 100 patients
with schizophrenia, 12 months before and 12 months
after initiation of RLAT [16]. A statistically significant
reduction (p < .01) was observed in the number of hos-
pitalizations in the 12 months after initiation of RLAT
compared with the 12 months before initiation: 62 ver-
sus 22 admissions, respectively.
In a European study of 397 patients treated with
RLAT [17], the number of patients requiring hospitaliza-
tion decreased significantly (p < .0001) from 38% during
the 12 weeks before study entry to 12% during the last
12 weeks of the study. The need for outpatient consulta-
tions also decreased significantly (p < .0001) from 70%
during the 12 weeks before study entry to 30% during
the first 12 weeks of treatment. The need for outpatient
consultations remained stable during the remainder of
the treatment period. No change in the number of ER
admissions was observed before or during RLAT
treatment.
Conversely, in a study in the United Kingdom, Young
a n dT a y l o rf o u n dt h a ts w i t c h i n gt oR L A Tw a sa s s o -
ciated with a continuing trend toward increased use of
health care resources [18]. In this study, resource utiliza-
tion data were collected for 3 years before and 1 year
Post-RLAT
Pre-RLAT
0.42
0.28
0.39
0.71
0.63
0.65
0.2 0.4 0.6 0.8 1 0
-40%
-56%
-41% Hospitalizations
(any reason)
% Reduction Number per Person-Year
Psychiatric
Hospitalizations
Emergency Room
Visits
-100 -80 -60 -40 -20
Figure 1 Change from Baseline in Hospitalization Incidence Rate. (pre-RLAT versus post-RLAT period [n = 435; p < .01 for all]).
Pre-RLAT
Post-RLAT
% Patients Hospitalized per Year
34.7%
20.7%
0% 10% 20% 30% 40%
Figure 2 Percentage of patients with >1 psychiatric-related
hospitalization.( n = 343; p < .0001).
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nia. The mean number of days spent in the hospital per
patient increased from 31 in year -3 to 44 in year -2, to
90 in year -1, and to 141 in year +1. The authors
acknowledge that these results may reflect a selection
bias because the patients studied tended to be more
severely ill; the majority (69.6%) of these individuals
were inpatients when RLAT was initiated. In fact, some
studies suggest that RLAT can decrease hospitalization
days. In a retrospective study at four sites in Germany
using a mirror-image design [19], hospitalization rates
and duration of inpatient treatment were assessed in
patients with schizophrenia and schizoaffective disorder
who were switched to RLAT treatment for 12 and 18
months, respectively. Patients who received RLAT had a
mean of 0.53 and 0.49 inpatient hospitalizations at 12
and 18 months, respectively, compared with 1.51 hospi-
talizations prior to receiving RLAT (p < .0001). Patients
w h os w i t c h e dt oR L A Ta l s os p e n t2 7 . 4a n d3 8 . 4f e w e r
days in an inpatient setting at 12 and 18 months,
respectively. Another, retrospective mirror-image analy-
sis of all patients prescribed RLAT over a 35-month
period in a United Kingdom psychiatric clinic also
examined hospitalizations [20]. In this study, RLAT use
compared with previous treatment was associated with a
reduction in the number of hospital admissions (33 vs
65; p < .005) and total inpatient days (2188 vs 4550
days; p < .005). Mean RLAT treatment period in this
study was 13.2 months.
As this was a nonrandomized, longitudinal, natura-
listic, observational study, with no concurrent com-
parator group, there are several limitations that may
influence the generalizability of the results. Patients
were permitted to receive additional medications at
the discretion of their clinicians and may or may not
have received RLAT at the time of the study visit.
Therefore, the reductions in health care resource uti-
lization observed cannot be attributed to any particu-
lar treatment with certainty. However, although
patients were permitted to receive additional medica-
tions, 76% who attended visit 9 were documented as
having used RLAT, suggesting that RLAT might have
contributed to the reductioni nr e s o u r c eu t i l i z a t i o n .
In addition, more than half the patients discontinued
the study, suggesting potential selection bias for
retaining patients to be responders to RLAT treat-
ment. Additionally, data on hospitalization were
obtained through patient and clinician reports; there-
fore, these data rely on the accuracy in reporting
hospitalizations.
Conclusions
In SOURCE, the percentage of patients hospitalized
decreased significantly after RLAT initiation, and
patients had fewer inpatient hospitalization and ER vis-
its. Interestingly, the results of this study are similar to
the results of several other studies that had a different
s t u d yd e s i g no rw e r ec o n d u c t e do u t s i d eo ft h eU n i t e d
States. Because of the high cost associated with hospita-
lization of patients with schizophrenia, these results sug-
gest that the initiation of RLAT treatment could result
in decreased health care costs.
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